key: cord-0961692-1kbn1m1e
authors: Biancari, Fausto; Mariscalco, Giovanni; Dalén, Magnus; Settembre, Nicla; Welp, Henryk; Perrotti, Andrea; Wiebe, Karsten; Leo, Enrico; Loforte, Antonio; Chocron, Sidney; Pacini, Davide; Juvonen, Tatu; Broman, L. Mikael; Perna, Dario Di; Yusuff, Hakeem; Harvey, Chris; Mongardon, Nicolas; Maureira, Juan P.; Levy, Bruno; Falk, Lars; Ruggieri, Vito G.; Zipfel, Svante; Folliguet, Thierry; Fiore, Antonio
title: Six-month Survival after Extracorporeal Membrane Oxygenation for Severe COVID-19
date: 2021-01-19
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2021.01.027
sha: b602039644f108cab1e68a42574b6f63d321cbdf
doc_id: 961692
cord_uid: 1kbn1m1e

OBJECTIVES: We evaluated the outcome of adult patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) requiring the use of extracorporeal membrane oxygenation (ECMO). DESIGN: Multicenter retrospective, observational study. SETTING: tertiary referral university and community hospitals. PARTICIPANTS: Patients with confirmed severe COVID-19-related ARDS. INTERVENTIONS: Venovenous- or venoarterial-ECMO. MEASUREMENTS AND MAIN RESULTS: 132 patients (mean age 51.1±9.7 years, females 17.4%) were treated with ECMO for confirmed severe COVID-19-related ARDS. Before ECMO, the mean Sequential Organ Failure Assessment (SOFA) score was 10.1±4.4, mean pH was 7.23±0.09 and mean PaO(2)/FiO(2) ratio was 77±50 mmHg. Venovenous-ECMO was adopted in 122 patients (92.4%) and venoarterial-ECMO in 10 patients (7.6%) (mean duration, 14.6±11.0 days). Sixty-three (47.7%) patients died on ECMO and 70 (53.0%) during the index hospitalization. Six-month all-cause mortality was 53.0%. Advanced age (per year, HR 1.026, 95%CI 1.000-1-052) and low pre-ECMO arterial pH (per unit, HR 0.006, 95%CI 0.000-0.083) were the only baseline variables associated with increased risk of 6-month mortality. CONCLUSIONS: The present findings suggest that about half of adult patients with severe COVID-19-related ARDS can be successfully managed with ECMO with sustained results at 6-month. Decreased arterial pH before ECMO was significantly associated with early mortality. Therefore, we hypothesize that initiation of ECMO therapy before severe metabolic derangements subset may significantly improve survival rates in these patients. These results should be viewed in the light of a strict patient selection policy and may not be replicated in patients with advanced age or multiple comorbidities. CLINICAL TRIAL REGISTRATION: Identifier, ____.

The outbreak of coronavirus disease 2019 (COVID-19) has led to a pandemic associated with a mortality ranging from 21% to 28% among hospitalized patients. 1,2,3 A large study from the New York City area hospitals showed that 14.2% of hospitalized patients were admitted to the intensive care unit (ICU) and 12% received invasive mechanical ventilation. 1 Mortality among patients who received mechanical ventilation was 88%. 1 A study from Northern Italy showed that, among 3988 COVID-19 patients admitted to ICUs of the Lombardy region of Italy, about 50% have died. 4 Acute respiratory distress syndrome (ARDS) is a common complication of COVID-19 and extracorporeal membrane oxygenation (ECMO) can be a salvage therapy in this dramatic medical context. However, ECMO therapy was not utilized in significant numbers in the first phase of the COVID-19 infection outbreak 4 and initially the Extracorporeal Life Support Organization (ELSO) has not clearly supported the use of ECMO in these patients. 5 Indeed, only 64 (1.7%) out of 3857 severe COVID-19 patients admitted to the ICUs of the Lombardy region of Italy were treated with ECMO and their ICU mortality was 62.5%. 4 Experience with influenza A(H1N1)-related ARDS patients showed that ECMO therapy was associated with a significantly lower hospital mortality compared to non-ECMO therapy (24.0% vs.

46.7%). 6 Consonant data were also observed in the Reseau Europeen de Recherche en Ventilation Artificielle (REVA) Research Network analysis for young patients with influenza A(H1N1)-related ARDS. 7 The results of a recent meta-analysis further consolidate the growing body of evidence of the benefits of ECMO in patients with ARDS. 8 Initial data on the treatment of severe COVID-19 patients from the Paris-Sorbonne University Hospital Network documented a 60-day mortality rate of 31%. 9 This excellent result was confirmed by a multicenter study by the ELSO which documented a hospital mortality of 37.4%. 10 However, these studies included also patients who were still on treatment during the index hospitalization and there is a lack of data on the mid-term outcome of patients who survived to discharge. In the present study, we aimed to evaluate the 6-month outcome of COVID-19 patients who were treated with ECMO for refractory ARDS from a multicenter study.

We conducted a retrospective cohort study of all patients who underwent ECMO of any configuration for confirmed COVID-19-related ARDS at ten ECMO centers in _______ countries (_______) (ClinicalTrials.gov identifier, _____). All participating centers, but one (____) were tertiary care university hospitals and designated COVID-19 ECMO centers. The study protocol was approved by the institutional or national review board of each participating center according to national legislations.

Informed consent was waived because of the retrospective nature of this study. The inclusion criteria for the study entry were adults aged 18 years or older with severe hypoxemia with or without hemodynamic instability refractory to conventional therapies associated with laboratory confirmed COVID-19-related ARDS. ARDS was defined according to the Berlin definition criteria. 11 Data were retrospectively collected into a dedicated electronic datasheet with pre-specified variables by experienced clinicians and underwent checking of its completeness and quality. Data on baseline characteristics, ECMO therapy and adverse events were retrieved from the electronic patient records.

Data on intermediate survival was retrieved from national registries, electronic patient records and by contacting patients and their general practitioners. Six-month follow-up was complete for all, but four patients whose follow-up ranged from 3.0 to 5.2 months.

The primary outcome of this study was all-cause mortality at 6 months from the initiation of ECMO therapy. The secondary outcomes included mortality on ECMO, ICU mortality, hospital mortality, lung or pleural complications requiring thoracic surgery, stroke, acute kidney injury, new renal replacement therapy, transfusion of blood products, blood stream infection, confirmed or suspected pulmonary embolism, duration of invasive mechanical ventilation and length of ICU and hospital stay.

ICU mortality was defined as all-cause mortality in the ICU where ECMO therapy was performed or in any ICU facility where the patient was transferred after weaning from ECMO. Stroke was defined as any focal or global neurological syndrome occurring during the ICU stay caused by ischemia and/or hemorrhage not resolving within 24 hours. The diagnosis of stroke was made based on findings at computed tomography and/or magnetic resonance imaging of the brain. Acute kidney injury was defined as an increase in serum creatinine concentration at least 1.5-fold the baseline level or a serum creatinine concentration ≥25.6 µmol/L or new renal replacement therapy from the initiation of ECMO therapy during the index hospitalization.

No sample size calculation was performed. Continuous variables are reported as mean and standard deviation, and categorical variables are reported as counts and percentages. Comparisons of baseline and treatment variables between the study groups were performed using the Kaplan-Meier and the Cox proportional hazards methods. Comparisons of between the study groups were performed using the Mann-Whitney U test, Fisher exact test, Kruskal-Wallis' test and χ 2 tests. Cox proportional hazards analysis was performed to identify risk factors for 6-month all-cause mortality by including into the regression model the following covariates with p<0.2 for 6-month mortality in univariate analysis: age, Tidal volume, pre-ECMO platelets count, pre-ECMO arterial pH, use of lopinavir/ritonavir and use of convalescent plasma. The receiver operating characteristics (ROC) curve analysis was performed to evaluate the predictive ability of continuous variables. The Youden's test was used to identify the best cutoff-value of continuous covariates in predicting early mortality. A classification and regression tree 

Between March 2, 2020 to April 30, 2020, 132 patients (mean age 51.1±9.7 years, females 17.4%) were treated with ECMO for confirmed severe COVID-19-related ARDS and/or hemodynamic instability at 10 centers (Tabs. 1,2). The number of patients treated with ECMO at each center varied from 2 to 44 patients (Tab. 1). Before initiation of ECMO therapy, the mean Sequential Organ Failure Assessment (SOFA) score was 10.1±4.4, mean pH was 7.23±0.09 and mean PaO 2 /FiO 2 ratio was 77±50 mmHg (Tab. 2).

Patients' age, SOFA score and pre-ECMO arterial pH differed significantly between centers (tab. 1).

Primary venovenous ECMO (VV-ECMO) was used in 122 patients (92.4%), while venoarterial ECMO (VA-ECMO) was used in ten patients (7.6%) because of coexistent hemodynamic instability (Tab. 3).

Eight (6.6%) patients on primary VV-ECMO had a second run of ECMO (5 VV-ECMO, 2 VA-ECMO and 1 veno-veno-arterial-ECMO) and a third run of ECMO (1 VV-ECMO and 1 veno-arterial-venous-ECMO). Six (60.0%) patients on primary VA-ECMO had a second run of ECMO (4 veno-arterialvenous-ECMO, 1 VV-ECMO and 1 VA-ECMO). A double lumen cannula was used for VV-ECMO in 23 patients (17.4%). Other ECMO configurations are summarized in Table 3 . Fourteen (10.6%) patients required conversion to another ECMO configuration and two (1.5%) patients required a third different ECMO configuration. Heparin was used for anticoagulation during ECMO to achieve an activated clotting time varying from 160 to 300 s or an activated partial thromboplastin time of 40 to 60 s according to different Institutional policies. The mean overall duration of ECMO therapy was 14.6±11.0 days.

Sixty-three (47.7%) patients died on ECMO and 70 (53.0%) patients died during the index hospitalization. Overall, 6-month all-cause mortality was 53.0% ( Fig. 1 ) and did not differ between centers (Log-rank, p=0.347) (Tab. 1). Ten (7.6%) patients required VA-ECMO as primary configuration had higher risk of death on ECMO (80.0% vs. 45.1%, p=0.034) as well as during index hospitalization (80.0% vs. 50.8%, p=0.075) and at 6-month (80.0% vs. 50.8%%, Log-rank test: p=0.008). Fourteen patients had their ECMO configuration changed, but they did not have significantly increased risk of death on ECMO (50.0% vs. 47.5%, p=0.857) as well as during index hospitalization (57.1% vs. 52.5%, p=0.744) and at 6-month (57.1% vs. 52.6%, Log-rank test: p=0.679).

The most frequent complications occurring during or immediately after ECMO therapy were acute kidney injury (64.1%), blood stream infection (31.8%), stroke (14.4%), confirmed or suspected pulmonary embolism (13.6%) and deep vein thrombosis (11.4%) (Tab. 4). One hundred and five (79.5%) patients required red blood cell transfusion (mean 7.8±13.5 units) (Tab. 4).

Cox proportional hazard analysis including pre-ECMO covariates showed that age (per year HR 1.026, 95%CI 1.000-1-052) and pre-ECMO arterial pH (per unit HR 0.006, 95%CI 0.000-0.083) were independent predictors of 6-month mortality. VA-ECMO configuration was not associated with increased 6-month mortality at multivariate analysis (adjusted HR 1.844, 95%CI 0.824-4.128). The Youden's test showed that the best cutoff value of pre-ECMO arterial pH to predict hospital mortality was 7.23 (arterial pH <7.23 72.9% vs. arterial pH ≥7.23 41.7%, p=0.001, sensitivity 50.0%, specificity 79.0%, area under the ROC curve 0.304, 95%CI 0.0.214-0.394). CART analysis showed that patients aged ≥60 years had a higher 6-month mortality compared to younger patients (68.2% vs. 50.0%) (Fig. 2) . A pre-ECMO pH <7.23 was associated with excessive 6-month mortality either in patients ≥60 years old (90.9%) and in those <60 years old (68.4%) (Fig. 2) . Significantly lower 6-month mortality was observed with pH ≥7.23 both in patients ≥60 years old (45.5%) and in younger patients (40.3%).

The findings of the present analysis can be summarized as follows: 1) half of relatively young adults with COVID-19-related ARDS can be salvaged using ECMO; 2) all these patients required prolonged ECMO therapy (mean 14.6 days) as well as long ICU (mean 30.5 days) and hospital stay (mean 36.6 days); 3) advanced age and decreased pH before initiation of ECMO were associated with prohibitive 6-month mortality; 4) mortality was <50% when ECMO was started before severe metabolic derangements subsided.

The outbreak of the COVID-19 pandemic resulted in high mortality amongst the vulnerable elderly. 12, 13 However, mortality is significant also among younger subjects with or without comorbidities. The prospective ISARIC WHO CCP-UK study showed that 26% of patients hospitalized with a diagnosis of COVID-19 died and 34% were still receiving care. 13 Similar figures were reported in previous studies. [1] [2] [3] [4] In the ISARIC WHO CCP-UK study, 13 patients who were treated with mechanical ventilation had a mean age of 61 years and 37% of them died while 46% were still receiving care.

In this scenario with high mortality and prolonged hospital treatment for severe COVID-19, the present analysis along with two previous studies 9, 10 documented that ECMO may be beneficial in many patients with severe COVID-19-related ARDS and/or hemodynamic instability. This information is of crucial importance when planning treatment of patients who are unresponsive to conventional medical therapies.

Based on the findings of these relatively large series, allocation of resources seems to be justified for ECMO treatment of young adults with severe COVID-19.

The early and small series of patients with ECMO for severe COVID-19 reported on excessive mortality rates with this salvage therapy. [14] [15] [16] Furthermore, the interpretation of the results was difficult because of incomplete follow-up of these patients. 17 Despite these discouraging initial results, experienced ECMO centers adopted an active approach toward the management of these critically ill patients and documented satisfactory early mortality rates. Schmidt et al. 9 reported the results of ECMO therapy in COVID-19 patients treated at the Paris-Sorbonne University Hospital Network including five ICUs. Eighty-three patients had a complete follow-up at 60-day and their mortality rate was 31%.

A large multicenter study by the ELSO investigators documented an in-hospital mortality at 90 days after ECMO of 37.4%. 10 Multivariate analysis of the ELSO registry showed that advanced age, the use of venoarterial-ECMO, low PaO 2 /FiO 2 , acute kidney injury, pulmonary disease, immunocompromised state and pre-ECMO cardiac arrest were independent predictors of in-hospital mortality. Importantly, higher adult 2019 hospital ECMO case volume was associated with improved outcome. 10 The present series shared similar patient's age and risk profile of those by Schmidt et al. 9 and Barbaro et al., 10 but documented an in-hospital and 6-month mortality rate of 53.0%, which is much higher than these previous multicenter studies. Our series included half of patients without any significant comorbidity and only 17% of patients had two or more comorbidities. Importantly, these risk factors did not have any impact on the early mortality. However, the large ELSO 10 report did not include data on pre-ECMO arterial pH and arterial lactate, which prevents any analysis of the clinical importance of pre-ECMO metabolic derangements. Schmidt et al. 9 reported a median arterial pH of 7.32 and of arterial lactate of 1.6 mmol/L before initiation of ECMO, while in our series the median arterial pH (7.26) and median arterial lactate (2.0 mmol/L) were poorer than those of the Schimdt's series. These findings suggest that, despite a similar age-based selection of patients, in the present study ECMO was often started when severe metabolic derangements had occurred. Indeed, CART analysis showed that 6-month mortality rate was below 45% when, independently of patients' age, the arterial pH was equal or higher than 7.23.

Therefore, we hypothesize that initiation of ECMO therapy before severe metabolic derangements subset might significantly improve survival rates in these patients as documented in prior studies.

This study showed that bleeding and thromboembolism are frequent complications among ECMO-treated COVID-19 patients (Tab. 3) . Prior studies demonstrated a hypercoagulability state related to COVID- 19 18,19 which may indicate anticoagulation as a valid preventative therapy in these patients. However, there is also evidence of a tendency to intracranial bleeding in COVID-19 patients, which is associated with poor prognosis. 20, 21 Bleeding complications are frequent during ECMO treatment 4, 22 and point-ofcare management should be considered when anticoagulation is started to reduce the risk of bleeding and to avoid ECMO circuit thrombosis.

Patients included in the present analysis were among the first ones who have been treated with ECMO therapy for COVID-19 related ARDS. At that time, ELSO did not clearly support the use of this therapy in COVID-19 patients. Therefore each institution decided on their treatment policy based on a strict patient selection and the availability of resources for this costly therapy. Analysis of the present data showed that ECMO was used in rather young patients (only 5.3% of patients were ≥65 years old) and without severe comorbidities. Some centers treated mostly patients aged less than 50 years and there was a significant inter-institutional differences also in pre-ECMO arterial pH levels (Tab. 1). Still, ECMO was used in a large number of diabetics and obese patients, but only 17% of patients had two or more comorbidities. Therefore, these results should be viewed in the light of a strict patient selection policy and may not be replicated in patients with advanced age or multiple comorbidities.

The retrospective nature is one of the main limitations of this study. Second, the lack of standardized selection criteria for starting and managing of ECMO treatment are major limitations of this study.

However, at the outbreak of COVID-19 pandemic there were not internationally recognized and specific criteria for starting ECMO treatment in these patients. Indeed, ECMO therapy was employed in these rather young patients mostly on compassionate basis. Third, conclusive results on the benefits of ECMO in these critically ill patients cannot be reached without a comparative analysis with conventionally treated patients. However, a randomized study is hardy feasible in this setting. In fact, the EOLIA study showed that the use of this salvage therapy in critically ill patients may lead to cross-over to ECMO in a significant proportion of control patients. 23 A previous study 8 

ARDS demonstrated that matching ECMO-treated patients with conventionally treated patients is problematic and may not provide conclusive results. Despite this limitation, severe respiratory failure and sepsis conditions as observed in this series are expected to be fatal in nearly all patients. Fourth, the limited size of this series prevents conclusive results on the risk factors which may contraindicate the use of ECMO in these critically ill patients. Finally, the multicenter nature of this study may introduce bias related to the volume and experience of each center, although this was rule out by the recent ELSO study. 10 On the contrary, the multicenter approach may even out single-center specifics and thus increase the generalizability of the results.

In conclusions, the present study showed in a cohort of relatively young adult patients with severe COVID-19-related ARDS, that almost half of them may be salvaged with ECMO support with sustained results at 6-month. Decreased arterial pH before ECMO was significantly associated with early mortality. Therefore, we hypothesize that initiation of ECMO therapy before severe metabolic derangements subset may significantly improve survival rates in these patients. These results should be viewed in the light of a strict patient selection policy and may not be replicated in patients with advanced age or multiple comorbidities.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ICU=intensive care unit, RBC=red blood cell, ECMO=extracorporeal membrane oxygenation.

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

Initial ELSO Guidance Document: ECMO for COVID-19

Patients with severe cardiopulmonary failure

Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1)

Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis

Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Acute respiratory distress syndrome: The Berlin definition

Epidemiology of COVID-19 in a long-term care facility in King County, Washington

Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study

Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports

Use of ECMO in patients with coronavirus disease 2019: does the evidence suffice?

Extracorporeal membrane oxygenation support in severe COVID-19

Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in coronavirus disease 2019: experience with 32 patients

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis

COVID-19 -associated diffuse leukoencephalopathy and microhemorrhages

Stroke in patients with SARS-CoV-2 infection: case series

Hemorrhage under veno-venous extracorporeal membrane oxygenation in acute respiratory distress syndrome patients: a retrospective data analysis

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome